Venus Concept Inc. (NASDAQ:VERO) Outshines in Capital Efficiency Among Peers

Venus Concept Inc. (NASDAQ:VERO) specializes in medical aesthetic technology, providing non-invasive and minimally invasive devices for aesthetic and medical applications. Despite its innovative offerings, VERO is currently trading at $3.18, with a target price of $1.64, indicating a potential downside of approximately -48.33%. This gap between the current and target prices reflects a pessimistic outlook from investment analysts, leading to its exclusion from coverage.

In contrast, Establishment Labs Holdings Inc. (NASDAQ:ESTA), a peer in the medical technology sector, is trading at $38 with a discounted cash flow (DCF) valuation of $64.84. This suggests a potential upside of 70.62%, highlighting its strong growth potential. ESTA's focus on breast aesthetics and reconstruction has positioned it as a leader in its niche, offering promising returns for investors.

AxoGen, Inc. (NASDAQ:AXGN), another peer, is trading at $10.92 with a DCF valuation of $11.66. This indicates a modest potential upside of 6.77%. AxoGen specializes in surgical solutions for peripheral nerve injuries, providing a steady growth outlook compared to its peers. While its potential upside is not as high as ESTA's, it still presents a positive investment opportunity.

Among these peers, Establishment Labs Holdings Inc. (ESTA) stands out with the highest target price change and growth potential of 70.62%. This significant upside reflects the company's strong market position and innovative product offerings in the medical aesthetics industry. Investors may find ESTA's growth prospects more appealing compared to VERO and AXGN.

• Venus Concept Inc. (NASDAQ:VERO) showcases efficient capital utilization with a ROIC of 174.86% significantly higher than its WACC of 17.20%.
• NeuroBo Pharmaceuticals and other peers exhibit negative ROIC to WACC ratios, indicating challenges in capital efficiency.
• Plus Therapeutics stands out among peers with a ROIC of 263.26% and a ROIC to WACC ratio of 44.18, highlighting superior capital efficiency.

Venus Concept Inc. (NASDAQ:VERO) is a company that specializes in medical aesthetic technology. It provides a range of non-invasive and minimally invasive devices for various aesthetic and medical applications. The company operates in a competitive market with peers like NeuroBo Pharmaceuticals, ThermoGenesis Holdings, Plus Therapeutics, Exicure, and Acutus Medical.

Venus Concept's ROIC of 174.86% is significantly higher than its WACC of 17.20%, resulting in a ROIC to WACC ratio of 10.16. This indicates that the company is generating returns well above its cost of capital, showcasing efficient capital utilization. This is a positive sign for investors as it suggests that the company is effectively using its resources to generate profits.

In comparison, NeuroBo Pharmaceuticals has a negative ROIC of -574.82% against a WACC of 5.00%, leading to a ROIC to WACC ratio of -114.95. This suggests that NeuroBo is not generating sufficient returns to cover its cost of capital, indicating inefficient capital use. Similarly, ThermoGenesis Holdings and Exicure also show negative ROIC to WACC ratios, reflecting challenges in capital efficiency.

Plus Therapeutics stands out with a ROIC of 263.26% and a WACC of 5.96%, resulting in a ROIC to WACC ratio of 44.18. This indicates that Plus Therapeutics is utilizing its capital more effectively than its peers, generating substantial returns relative to its cost of capital. This positions Plus Therapeutics as a leader in capital efficiency among its peers.

Acutus Medical, with a ROIC of -0.24% and a WACC of 16.09%, has a ROIC to WACC ratio of -0.01, indicating that it is barely covering its cost of capital. This suggests that Acutus Medical may need to improve its capital utilization to enhance its financial performance.

Venus Concept Inc. (NASDAQ:VERO) is a leading figure in the global medical aesthetic technology sector, focusing on the development and commercialization of innovative, non-invasive devices for aesthetic and medical treatments. As part of its strategy to maintain a competitive edge in the fast-paced industry, Venus Concept has made a significant financial decision. On March 4, 2025, VERO executed a reverse stock split at a ratio of 11-for-1, a move approved by the company's stockholders on February 14, 2025.

This adjustment was aimed at increasing the bid price of the company's common stock, thereby enhancing its attractiveness to investors. The reverse stock split became effective at 5:00 p.m. Eastern Standard Time on March 3, 2025, with VERO commencing trading on a split-adjusted basis on The Nasdaq Capital Market the next day.

This strategic decision is anticipated to potentially increase the market price of the stock. Prior to the reverse stock split, VERO's stock was trading at $0.28, marking a decrease of approximately 8.14% with a change of -$0.02. Throughout the day, the stock experienced fluctuations, reaching a low of $0.25 and a high of $0.30. Over the past year, the stock hit a peak of $1.59 and a trough of $0.25. With a market capitalization of approximately $2.03 million and a trading volume of 391,148 shares on the NASDAQ exchange, VERO's reverse stock split represents a strategic effort to bolster the stock's performance and attract a broader investor base by increasing its price per share.

Venus Concept Inc. (NASDAQ:VERO) is a leading figure in the global medical aesthetic technology sector, focusing on the development and commercialization of innovative, non-invasive devices for aesthetic and medical treatments. As part of its strategy to maintain a competitive edge in the fast-paced industry, Venus Concept has made a significant financial decision. On March 4, 2025, VERO executed a reverse stock split at a ratio of 11-for-1, a move approved by the company's stockholders on February 14, 2025.

This adjustment was aimed at increasing the bid price of the company's common stock, thereby enhancing its attractiveness to investors. The reverse stock split became effective at 5:00 p.m. Eastern Standard Time on March 3, 2025, with VERO commencing trading on a split-adjusted basis on The Nasdaq Capital Market the next day.

This strategic decision is anticipated to potentially increase the market price of the stock. Prior to the reverse stock split, VERO's stock was trading at $0.28, marking a decrease of approximately 8.14% with a change of -$0.02. Throughout the day, the stock experienced fluctuations, reaching a low of $0.25 and a high of $0.30. Over the past year, the stock hit a peak of $1.59 and a trough of $0.25. With a market capitalization of approximately $2.03 million and a trading volume of 391,148 shares on the NASDAQ exchange, VERO's reverse stock split represents a strategic effort to bolster the stock's performance and attract a broader investor base by increasing its price per share.

• Venus Concept Inc. (NASDAQ:VERO) reported an earnings per share (EPS) of -$1.28, missing the estimated EPS of -$1.20.
• The company's revenue for the quarter was $9.92 million, significantly below the estimated $17.28 million.
• VERO reported a net loss of about $9.3 million, with negative operating income and EBITDA of $7.16 million.

Venus Concept Inc. (NASDAQ:VERO) is a prominent player in the global medical aesthetic technology sector. The company specializes in developing and commercializing innovative technologies for non-invasive aesthetic treatments. Despite its strong market presence, VERO faces competition from other companies in the medical aesthetics industry, which can impact its financial performance.

On November 13, 2024, VERO reported its earnings for the third quarter of the fiscal year. The company revealed an earnings per share (EPS) of -$1.28, slightly missing the estimated EPS of -$1.20. This indicates that the company's profitability was lower than analysts had anticipated, which can affect investor confidence.

VERO's actual revenue for the quarter was approximately $9.92 million, significantly below the estimated $17.28 million. This shortfall in revenue suggests challenges in meeting sales expectations, which could be due to various factors such as market competition or changes in consumer demand.

During the Q3 2024 earnings conference call, key company leaders, including CEO Rajiv De Silva, discussed the financial performance and strategic initiatives. Despite generating a gross profit of $9.92 million, VERO reported a net loss of about $9.3 million, highlighting the company's struggle to achieve profitability.

The company's operating income and EBITDA were both negative at $7.16 million, reflecting ongoing financial challenges. Additionally, VERO's income before tax was a loss of approximately $9.33 million, with an income tax expense of $31,000. These figures underscore the need for strategic adjustments to improve financial outcomes.

• Venus Concept Inc. (NASDAQ:VERO) reported an earnings per share (EPS) of -$1.28, missing the estimated EPS of -$1.20.
• The company's revenue for the quarter was $9.92 million, significantly below the estimated $17.28 million.
• VERO reported a net loss of about $9.3 million, with negative operating income and EBITDA of $7.16 million.

Venus Concept Inc. (NASDAQ:VERO) is a prominent player in the global medical aesthetic technology sector. The company specializes in developing and commercializing innovative technologies for non-invasive aesthetic treatments. Despite its strong market presence, VERO faces competition from other companies in the medical aesthetics industry, which can impact its financial performance.

On November 13, 2024, VERO reported its earnings for the third quarter of the fiscal year. The company revealed an earnings per share (EPS) of -$1.28, slightly missing the estimated EPS of -$1.20. This indicates that the company's profitability was lower than analysts had anticipated, which can affect investor confidence.

VERO's actual revenue for the quarter was approximately $9.92 million, significantly below the estimated $17.28 million. This shortfall in revenue suggests challenges in meeting sales expectations, which could be due to various factors such as market competition or changes in consumer demand.

During the Q3 2024 earnings conference call, key company leaders, including CEO Rajiv De Silva, discussed the financial performance and strategic initiatives. Despite generating a gross profit of $9.92 million, VERO reported a net loss of about $9.3 million, highlighting the company's struggle to achieve profitability.

The company's operating income and EBITDA were both negative at $7.16 million, reflecting ongoing financial challenges. Additionally, VERO's income before tax was a loss of approximately $9.33 million, with an income tax expense of $31,000. These figures underscore the need for strategic adjustments to improve financial outcomes.